249 related articles for article (PubMed ID: 37619813)
1. Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies.
Shimizu K; Kahramanian A; Jabbar MADA; Turna Demir F; Gokyer D; Uthamacumaran A; Rajan A; Saad MA; Gorham J; Wakimoto H; Martuza RL; Rabkin SD; Hasan T; Wakimoto H
Cancer Lett; 2023 Sep; 572():216363. PubMed ID: 37619813
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
4. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.
Sgubin D; Wakimoto H; Kanai R; Rabkin SD; Martuza RL
Stem Cells Transl Med; 2012 Apr; 1(4):322-32. PubMed ID: 23197811
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
8. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.
Nigim F; Esaki S; Hood M; Lelic N; James MF; Ramesh V; Stemmer-Rachamimov A; Cahill DP; Brastianos PK; Rabkin SD; Martuza RL; Wakimoto H
Neuro Oncol; 2016 Sep; 18(9):1278-87. PubMed ID: 26951380
[TBL] [Abstract][Full Text] [Related]
9. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
11. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract][Full Text] [Related]
12. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
Nguyen HM; Bommareddy PK; Silk AW; Saha D
Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword.
Blitz SE; Kappel AD; Gessler FA; Klinger NV; Arnaout O; Lu Y; Peruzzi PP; Smith TR; Chiocca EA; Friedman GK; Bernstock JD
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163730
[TBL] [Abstract][Full Text] [Related]
15. OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment.
Liu S; Li F; Ma Q; Du M; Wang H; Zhu Y; Deng L; Gao W; Wang C; Liu Y; Zhao Z; Liu H; Wang R; Tian Y; Hu M; Wan Y; Lu W; Zhang M; Zhao M; Cao Y; Zhang H; Wang W; Wang H; Wang Y
Theranostics; 2023; 13(12):4016-4029. PubMed ID: 37554264
[No Abstract] [Full Text] [Related]
16. Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation.
Sugawara K; Iwai M; Ito H; Tanaka M; Seto Y; Todo T
Mol Ther Oncolytics; 2021 Sep; 22():129-142. PubMed ID: 34514094
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic virus therapy for malignant gliomas: entering the new era.
Fudaba H; Wakimoto H
Expert Opin Biol Ther; 2023 Mar; 23(3):269-282. PubMed ID: 36809883
[TBL] [Abstract][Full Text] [Related]
18. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.
Zhang W; Fulci G; Wakimoto H; Cheema TA; Buhrman JS; Jeyaretna DS; Stemmer Rachamimov AO; Rabkin SD; Martuza RL
Neoplasia; 2013 Jun; 15(6):591-9. PubMed ID: 23730207
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
Kardani K; Sanchez Gil J; Rabkin SD
Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
[TBL] [Abstract][Full Text] [Related]
20. Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity.
Tian L; Xu B; Chen Y; Li Z; Wang J; Zhang J; Ma R; Cao S; Hu W; Chiocca EA; Kaur B; Caligiuri MA; Yu J
Nat Cancer; 2022 Nov; 3(11):1318-1335. PubMed ID: 36357700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
